Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06332677
Status:
RECRUITING
Last Update Posted:
2024-03-27
First Post:
2024-03-08
Brief Title:
Target of Suv420h12 in Hepatocytes
Sponsor:
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Organization:
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Study Overview
Official Title:
Targeting the Epigenetic Regulators Suv420h12 in Hepatocytes to Treat Nonalcoholic Fatty Liver Disease
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Nonalcoholic fatty liver disease NAFLD is globally the leading cause of liver disease and frequently progresses to cirrhosis and liver cancer The identification of effective drugs is the main unmet clinical need Changes in liver histones methylation accompanies the development and progression of NAFLD Our preliminary data demonstrate that inactivation of the methyltransferases SUV420H12 in hepatocytes protects mice against NAFLD In this project we propose to examine the relevance of these findings by evaluating the impact of genetic deletion of hepatic SUV420H12 in mice fed a steatogenic diet To further evaluate the potential for clinical translation of these results we will next 1 evaluate the expression of SUV420H12 in human liver transcriptomic data and 2 analyze the impact of genetic variations on disease outcomes in population-based cohorts 3 test an innovative therapeutic approach based on hepatocyte-targeted antisense oligonucleotides downregulating SUV420H12 in human liver organoidsassembloids
Detailed Description:
Nonalcoholic fatty liver disease NAFLD the leading cause of liver damage worldwide is characterized by liver fat accumulation and association with insulin resistance and frequently progresses to steatohepatitis NASH ultimately leading to cirrhosis and liver cancer
NAFLDNASH is becoming globally a leading cause of liver-related morbidity and mortality and by altering liver function contributes more widely to the burden of cardiometabolic renal and neoplastic diseases In the presence of concomitant hepatotoxic factors such as in particular atrisk alcohol intake and some medications defined in this case as metabolic dysfunction associated fatty liver disease or MAFLD synergizes with them representing a major driver of liver disease progression However for those with advanced disease or who cannot successfully change their diet and lifestyle no effective treatment is yet available to prevent or treat this condition which is therefore projected to become a major public health threat in the next decade Although understanding the mechanisms of NAFLD development and progression is essential for its preventiontreatment molecular players involved in its progression are poorly defined Recently an epigenetic component is recognized in this disorder and the histone methyltransferases SUV420H12 are promising candidates for this function Multiple evidences connect lipid and iron metabolism in the hepatocyte 1 Genome Wide Association Studies GWAS in human populations showed an overlap of loci affecting iron and lipid metabolism and excess iron in hepatocytes favors dyslipidemia and NAFLD 2 upregulation of the liver hormone hepcidin under the control by the BMP-SMAD pathway is protective against NAFLD-NASH Interestingly a GWAS performed in mouse strains kept on high-iron diet identified a shared association between liver iron and triglyceride levels at a region of chromosome 7 encompassing the histone methyltransferase Suv420h2 Our preliminary data show that mice with Suv420h inactivation in adipose tissue are resistant to diet-induced liver steatosis due to increased PPAR signaling Since mice with liver BMP-SMAD pathway upregulation showed Suv420h downregulation we hypothesize that the protective effect of increased hepatocyte BMP-SMAD signaling on NAFLD development is due to Suv420h In agreement Suv420h inactivation in hepatocytes counteracts diet-induced NAFLD as highlighted by our preliminary results
The present study is part of the RF project Ricerca Finalizzata - Project code RF-2021-12373889 funded by the grant call of the Ministery of Health 2020-2021 In the attached project we proposed 3 different aims
To characterize the disease progression in Suv420h12-liver conditional KO mice and to identify
To examine the impact of SUV420H12 genetic epigenetic and transcriptional variability on clinical outcomes for the identification of novel biomarkers of NAFLD-NASH
To propose and test an innovative therapeutic approach based on hepatocyte-targeted antisense oligonucleotides ASOs against Suv420h12 in preclinical models in mice and in human liver organoids and assembloids The present clinical study protocol will focus on the clinical aspects and procedures that will regard an intervention on data and sample of clinical cohorts Further details about the analyses conducted in animal models for which a specific Authorization has been requested can be found in the attached project
NAFLDNASH is becoming globally a leading cause of liver-related morbidity and mortality and by altering liver function contributes more widely to the burden of cardiometabolic renal and neoplastic diseases In the presence of concomitant hepatotoxic factors such as in particular atrisk alcohol intake and some medications defined in this case as metabolic dysfunction associated fatty liver disease or MAFLD synergizes with them representing a major driver of liver disease progression However for those with advanced disease or who cannot successfully change their diet and lifestyle no effective treatment is yet available to prevent or treat this condition which is therefore projected to become a major public health threat in the next decade Although understanding the mechanisms of NAFLD development and progression is essential for its preventiontreatment molecular players involved in its progression are poorly defined Recently an epigenetic component is recognized in this disorder and the histone methyltransferases SUV420H12 are promising candidates for this function Multiple evidences connect lipid and iron metabolism in the hepatocyte 1 Genome Wide Association Studies GWAS in human populations showed an overlap of loci affecting iron and lipid metabolism and excess iron in hepatocytes favors dyslipidemia and NAFLD 2 upregulation of the liver hormone hepcidin under the control by the BMP-SMAD pathway is protective against NAFLD-NASH Interestingly a GWAS performed in mouse strains kept on high-iron diet identified a shared association between liver iron and triglyceride levels at a region of chromosome 7 encompassing the histone methyltransferase Suv420h2 Our preliminary data show that mice with Suv420h inactivation in adipose tissue are resistant to diet-induced liver steatosis due to increased PPAR signaling Since mice with liver BMP-SMAD pathway upregulation showed Suv420h downregulation we hypothesize that the protective effect of increased hepatocyte BMP-SMAD signaling on NAFLD development is due to Suv420h In agreement Suv420h inactivation in hepatocytes counteracts diet-induced NAFLD as highlighted by our preliminary results
The present study is part of the RF project Ricerca Finalizzata - Project code RF-2021-12373889 funded by the grant call of the Ministery of Health 2020-2021 In the attached project we proposed 3 different aims
To characterize the disease progression in Suv420h12-liver conditional KO mice and to identify
To examine the impact of SUV420H12 genetic epigenetic and transcriptional variability on clinical outcomes for the identification of novel biomarkers of NAFLD-NASH
To propose and test an innovative therapeutic approach based on hepatocyte-targeted antisense oligonucleotides ASOs against Suv420h12 in preclinical models in mice and in human liver organoids and assembloids The present clinical study protocol will focus on the clinical aspects and procedures that will regard an intervention on data and sample of clinical cohorts Further details about the analyses conducted in animal models for which a specific Authorization has been requested can be found in the attached project
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None